Table 1.
Baseline characteristics of study groups.
| Patient characteristics | Total |
TAF |
TDF |
ETV |
p value∗ |
|---|---|---|---|---|---|
| (n = 75,816) | (n = 25,680) | (n = 26,954) | (n = 23,182) | ||
| Before propensity score matching | |||||
| Age (years) | 50.2 ± 12.5 | 48.0 ± 11.6 | 48.7 ± 12.2 | 54.4 ± 12.8 | <0.001 |
| Male, (%) | 43,663 (57.6) | 14,623 (56.9) | 11,721 (57.8) | 13,449 (58) | 0.033 |
| Duration of antiviral medication (days) | 788.1 ± 517.3 | 826.6 ± 502.8 | 809.3 ± 518.3 | 720.9 ± 525.3 | <0.001 |
| Proportion of liver cirrhosis, n (%) | 16,108 (21.2) | 6,188 (24.1) | 5,193 (19.3) | 4,727 (20.4) | <0.001 |
| Decompensation at start of antiviral therapy, n (%) | 6,837 (8.4) | 1,413 (5.5) | 2,463 (9.1) | 2,511 (10.8) | <0.001 |
| Charlson Comorbidity Index score | 2.8 ± 1.6 | 2.4 ± 0.9 | 2.7 ± 1.4 | 3.4 ± 2.2 | <0.001 |
|
Total |
TAF |
TDF |
ETV |
||
| (n = 52,611) | (n = 17,537) | (n = 17,537) | (n = 17,537) | p value∗ | |
| After propensity score matching | |||||
| Age (years) | 50.6 ± 11.1 | 50.6 ± 11.1 | 50.6 ± 11.1 | 50.6 ± 11.1 | 1.0 |
| Male, (%) | 29,706 (56.5) | 9,902 (56.5) | 9,902 (56.5) | 9,902 (56.5) | >0.999 |
| Duration of antiviral medication (days) | 800.8 ± 518.6 | 819.1 ± 501.2 | 816.6 ± 518.4 | 766.9 ± 533.9 | <0.001 |
| Proportion of liver cirrhosis, n (%) | 10,482 (19.9) | 3,494 (19.9) | 3,494 (19.9) | 3,494 (19.9) | >0.999 |
| Decompensation at start of antiviral therapy, n (%) | 3,459 (6.6) | 1,153 (6.6) | 1,153 (6.6) | 1,153 (6.6) | >0.999 |
| Charlson Comorbidity Index score | 2.7 ± 1.5 | 2.4 ± 1.0 | 2.6 ± 1.4 | 3.2 ± 2.0 | <0.001 |
∗
Group differences were evaluated using the χ2 test for categorical variables and the Student’s t test for continuous variables. ETV, entecavir; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.